Table 2 Comparisons of clinical variables of subjects with a favorable or unfavorable prognosis

Variable

Unfavorable prognosis

(N = 250)

Favorable prognosis

(N = 132)

p-value

Unfavorable prognosis

(N = 198)

Favorable prognosis

(N = 184)

p-value

Age

66.62 ± 13.11

61.7 ± 12.4

<0.001^*

66.84 ± 13.33

62.85 ± 12.48

0.003^*

Sex

0.100

0.004^*

Female

99(39.6%)

41(31.06%)

86(43.43%)

54(29.35%)

Male

151(60.4%)

91(68.94%)

112(56.57%)

130(70.65%)

Days of admission

15.5(9–24)

9(6.41–13)

<0.001^*

16.83(10–26)

9.31(7–14)

<0.001^*

BMI (kg/m²)

24.25 ± 3.94

24.34 ± 3.96

0.837

24.33 ± 4.04

24.24 ± 3.85

0.834

GCS

12.95 ± 2.62

13.94 ± 1.94

<0.001^*

ND

ND

ND

WBC

7.6(6.2–9.6)

8(6.6–10)

0.109

ND

ND

ND

RBC

4.69(4.32–5)

4.67(4.29–5.05)

0.803

4.7(4.29–5.01)

4.68(4.33–5.02)

0.741

Hb

14.01 ± 1.76

14.07 ± 1.92

0.771

ND

ND

ND

Hct

41.51 ± 4.53

41.45 ± 4.9

0.902

ND

ND

ND

PL

198(165–237)

216(181–254)

0.012^*

ND

ND

ND

PT

10.9(10.3–11.5)

10.8(10.3–11.4)

0.198

11(10.5–11.7)

10.7(10.3–11.3)

0.002^*

APTT

25.6(24.3–27.3)

26.3(24.3–28)

0.221

25.45(24.3–27.2)

26.1(24.4–27.9)

0.139

ALB

3.75(3.4–4.09)

3.79(3.45–4.09)

0.501

ND

ND

ND

LDL

110(92–131)

114(95–137)

0.23

ND

ND

ND

HDL

43.5(37.65–52)

40(35–51)

0.064

ND

ND

ND

TCHO

178.5(157–203)

183(158–206)

0.353

ND

ND

ND

TG

94.5(74.5–140.5)

109(83–154)

0.034^*

ND

ND

ND

BUN

14.75(12–20)

12.05(9.55–16.85)

0.001^*

ND

ND

ND

UA

5.42 ± 1.73

5.68 ± 1.49

0.187

ND

ND

ND

AST

28(21–37)

24(19–29)

<0.001^*

ND

ND

ND

ALT

23(17–32)

21(17–30)

0.133

ND

ND

ND

Cr

0.95(0.8–1.17)

0.9(0.76–1.1)

0.125

ND

ND

ND

Glucose

128(109–163)

119.5(99–148)

0.032^*

ND

ND

ND

Hb1

6(5.7–6.9)

5.8(5.6–6.3)

0.053

ND

ND

ND

CRP

17.1(5.59–61.16)

9.07(3.09–30.78)

0.007^*

ND

ND

ND

Na

139(137.4–141)

138.85(137–140)

0.162

ND

ND

ND

K

3.7(3.5–4)

3.7(3.31–3.94)

0.231

ND

ND

ND

Segment

60.76 ± 12.46

61.54 ± 12.14

0.564

ND

ND

ND

Lymphocyte

30.15 ± 11.56

30.05 ± 10.61

0.934

ND

ND

ND

SPG

1.02(1.01–1.02)

1.01(1.01–1.02)

<0.001^*

1.02(1.01–1.02)

1.01(1.01–1.02)

<0.001^*

SBP

150(133–162)

143.5(129–157)

0.031^*

150(133–162)

146(130–158)

0.098

NIHSS-Entry

14(9–19)

8.5(6–13)

<0.001^*

ND

ND

ND

NIHSS-Discharge

10(6–17)

2(0–4)

<0.001^*

ND

ND

ND

Complication

Infection

<0.001^*

<0.001^*

No

156(62.4%)

119(90.15%)

116(58.59%)

159(86.41%)

Yes

94(37.6%)

13(9.85%)

82(41.41%)

25(13.59%)

Hemorrhage

<0.001^*

0.004^*

No

226(90.4%)

131(99.24%)

178(89.9%)

179(97.28%)

Yes

24(9.6%)

1(0.76%)

20(10.1%)

5(2.72%)

Gout

0.378

0.973

No

233(93.2%)

126(95.45%)

186(93.94%)

173(94.02%)

Yes

17(6.8%)

6(4.55%)

12(6.06%)

11(5.98%)

Proteinuria

<0.001^*

<0.001^*

No

116(53.21%)

78(75%)

82(48.24%)

112(73.68%)

Yes

102(46.79%)

26(25%)

88(51.76%)

40(26.32%)

Bun/Cr

0.012^*

0.101

<15--Non-dehydration

100(42.74%)

64(57.14%)

82(43.39%)

82(52.23%)

≥15--Dehydration

134(57.26%)

48(42.86%)

107(56.61%)

75(47.77%)

Toast Dx

0.001^*

Cardioembolism

94(37.6%)

33(25%)

ND

ND

Lacune

30(12%)

39(29.55%)

ND

ND

Large-artery atherosclerosis

56(22.4%)

24(18.18%)

ND

ND

Other determined

3(1.2%)

1(0.76%)

ND

ND

Undetermined

57(22.8%)

30(22.73%)

ND

ND